ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Page, C.
Right arrow Articles by Costello, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Page, C.
Right arrow Articles by Costello, J.
Eur Respir J 1998; 12: 24-29
Copyright © ERS Journals Ltd 1998


Clinical Trial

Effect of chronic theophylline treatment on the methacholine dose-response curve in allergic asthmatic subjects

CP Page, T Cotter, S Kilfeather, P Sullivan, D Spina, and JF Costello

Theophylline is a bronchodilator and immunomodulator drug which has recently been demonstrated to attenuate the recruitment and activation of inflammatory cells into lungs of asthmatics. This study investigated the effect of chronic treatment with theophylline for its ability to alter airway responsiveness, as indicated by changes in airway sensitivity and reactivity to inhaled methacholine. The subjects studied were mild asthmatics who relied on beta-agonist medication only and who were randomized into two groups, one receiving theophylline (median dose 250 mg twice daily; range 250-375 mg twice daily) and the other placebo. A number of parameters was measured before and after treatment, including baseline forced expiratory volume in one second (FEV1), the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20; sensitivity), dose-response slope (reactivity) and percentage eosinophils, eosinophil cationic protein and T-cell markers in peripheral blood (by flow cytometry). After 2 months of treatment with theophylline there was a significant lowering of airway reactivity (slope) to methacholine and improvement in methacholine sensitivity (PC20). However, such changes were not associated with any significant change in the number or activation status of eosinophils and lymphocytes in peripheral blood. In conclusion, chronic treatment with theophylline reduces the reactivity of the airways to methacholine, which might be beneficial in the treatment of persistent asthma. The cellular mechanisms of this improvement remain to be clarified.


This article has been cited by other articles:


Home page
ChestHome page
Y. Y. Koh, Y. Park, and C. K. Kim
Maximal Airway Response in Adolescents With Long-term Asthma Remission and Persisting Airway Hypersensitivity: Its Profile and the Effect of Inhaled Corticosteroids
Chest, October 1, 2002; 122(4): 1214 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, and P. J. Barnes
A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression
PNAS, June 25, 2002; 99(13): 8921 - 8926.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
Y. Y. Koh, Y. H. Sun, H. S. Lim, C. K. Kim, and S. J. Hong
Effect of Inhaled Budesonide on Bronchial Hyperresponsiveness in Adolescents With Clinical Remission of Asthma
Chest, October 1, 2001; 120(4): 1140 - 1146.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.